Publications by authors named "Millie Garg"

Purpose: Serious games (SGs) have great potential for pediatric medical education. This study evaluated the efficacy of a SG in improving learner satisfaction, knowledge, and behavior.

Materials And Methods: This was an investigator-blinded randomized controlled trial (RCT) comparing a SG against two controls: (i) adaptive tutorial (AT), and (ii) low-stimulus control (LSC).

View Article and Find Full Text PDF

Intestinal bacterial dysbiosis is evident in children with cystic fibrosis (CF) and intestinal viruses may be contributory, given their influence on bacterial species diversity and biochemical cycles. We performed a prospective, case-control study on children with CF and age and gender matched healthy controls (HC), to investigate the composition and function of intestinal viral communities. Stool samples were enriched for viral DNA and RNA by viral extraction, random amplification and purification before sequencing (Illumina MiSeq).

View Article and Find Full Text PDF

Background: Cystic fibrosis (CF) is a multisystem disease and the importance of growth and nutrition has been well established, given its implications for lung function and overall survival. It has been established that intestinal dysbiosis (i.e.

View Article and Find Full Text PDF

Intestinal dysbiosis has been observed in children with cystic fibrosis (CF), yet the functional consequences are poorly understood. We investigated the functional capacity of intestinal microbiota and inflammation in children with CF. Stool samples were collected from 27 children with CF and 27 age and gender matched healthy controls (HC) (aged 0.

View Article and Find Full Text PDF

Background: Children with CF have been reported to consume significantly more energy-dense, nutrient-poor foods than controls where there are now concerns of inadequate micronutrient intake. There are no current or comprehensive dietary studies assessing micronutrient intake in CF children.

Objectives: To evaluate micronutrient intake in children with CF compared to recommended dietary intakes (RDIs).

View Article and Find Full Text PDF
Article Synopsis
  • * A study observed that treatment with ivacaftor, a CFTR potentiator, led to a significant decrease in the inflammatory marker calprotectin and an increase in beneficial gut bacteria (Akkermansia) among 16 CF patients over approximately 6 months.
  • * The findings suggest that ivacaftor may improve gut health in CF patients by promoting a healthier microbiome and reducing intestinal inflammation in those with specific CFTR mutations.
View Article and Find Full Text PDF

Background: The purpose of this study is to determine whether direct involvement by dietitians in parenteral nutrition (PN) ordering resulted in a reduction in PN prescriptions errors.

Methods: A prospective audit of PN prescriptions was undertaken at a pediatric hospital over 50 weeks. Prescriptions for PN that had dietitian involvement (dietitian group) were compared with prescriptions in which dietitians were not directly involved (nondietitian group).

View Article and Find Full Text PDF

Background: The pathogenesis of gut inflammation, bacterial dysbiosis and increased rates of malignancy in CF is unclear. Fecal M2-pyruvate kinase (M2-PK) is a biomarker indicative of cellular proliferation that may be raised in intestinal malignancy and inflammation. Biomarkers, including M2-PK, may be useful in assessing effects of novel therapies on the gastrointestinal tract.

View Article and Find Full Text PDF

Background: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF).

Method: Stools from CF patients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends.

Results: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected.

View Article and Find Full Text PDF

Purpose Of Review: Intestinal inflammation, dysbiosis, and increased gastrointestinal malignancy risks are well-described in patients with cystic fibrosis (CF). However, there is limited understanding of their pathophysiology. This review aims to discuss these issues and assess potential links between them.

View Article and Find Full Text PDF